Relmada Therapeutics (RLMD)
(Delayed Data from NSDQ)
$2.77 USD
-0.03 (-1.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.74 -0.03 (-1.08%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RLMD 2.77 -0.03(-1.07%)
Will RLMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RLMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RLMD
Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate
RLMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study
Other News for RLMD
Rising High: Clearmind granted patent approval for binge behavior treatment
Rising High: Exclusive talk with psilocybin CPG brand PATOO
Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (RLMD) and Neumora Therapeutics, Inc. (NMRA)
Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript
Optimistic Outlook for Relmada Therapeutics: Strategic Trial Enhancements and Solid Financial Position